Research and discovery in the age of AI: How leading teams are pushing the boundaries of biotech
Thursday, December 3, 2026, – (Europe/London)
Room: Threadneedle Hub · Industry speaker
Discover how LabGenius and Alchemab are applying machine learning to antibody-based drug discovery. LabGenius shows how an integrated, automated experimental and computational infrastructure enables cycle-based, multi-objective optimisation of multispecific antibodies, including T-cell engagers, through high-throughput data generation and active learning. Alchemab explains how its Resilome™ platform pairs antibody language models with sequences from disease-resilient individuals to identify novel targets and therapeutics. The approach produced ATLX-1282, a first-in-class ALS therapy that progressed into Phase 1 in less than three years.
Speakers
-
VP, Computational Sciences and Engineering, LabGenius -
Vice President of Technology, Alchemab Therapeutics